Streetbeat News

Stock Prices

GNPX

Genprex, Inc. will present preclinical data on its Reqorsa Gene Therapy at the 2024 EORTC-NCI-AACR Symposium. The therapy shows promise in overcoming resistance in lung cancer, and demonstrates tumor suppression in mesothelioma and glioblastoma.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 1:30 pm

INDV

Indivior PLC (NASDAQ:INDV) has cut its FY24 net revenue guidance due to competition and market pressures affecting its SUBLOCADE product. The company reported preliminary Q3 revenue results and expects lower-than-anticipated net revenue for SUBLOCADE. Indivior's shares fell 16.6% premarket.

Portfolio Pulse from Lekha Gupta

October 10, 2024 | 1:28 pm

MASI

TVTX

Travere Therapeutics and Masimo Corp are currently overbought stocks in the healthcare sector, with high RSI values indicating potential short-term price corrections. Travere's stock surged after pausing a Phase 3 study, while Masimo faces leadership changes and legal issues.

Portfolio Pulse from Avi Kapoor

October 10, 2024 | 1:21 pm

AI

BABA

LOT

MADE

NVDA

PLTR

QQQ

TSLA

WAY

YINN

The article lists the top 10 trending stocks on WallStreetBets as of October 10, 2024, according to Swaggy Stocks. The stocks mentioned include TSLA, NVDA, WAY, LOT, MADE, PLTR, YINN, AI, QQQ, and BABA.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 1:12 pm

JPM

WFC

Analysts are closely watching JPMorgan Chase & Co (JPM) and Wells Fargo & Co (WFC) ahead of their Q3 earnings on Oct. 11. JPMorgan shows strong bullish signals with a current price above its target and moving averages, while Wells Fargo has a promising outlook with a higher potential upside.

Portfolio Pulse from Surbhi Jain

October 10, 2024 | 1:10 pm

DIA

SPY

UUP

September's inflation data showed a slower decline than expected, with core inflation rising unexpectedly. Jobless claims spiked, complicating the Federal Reserve's interest rate outlook. Market reactions included a higher probability of a rate cut, a drop in the U.S. dollar index, and slight declines in major U.S. indices.

Portfolio Pulse from Piero Cingari

October 10, 2024 | 1:07 pm

TPST

Tempest Therapeutics Inc. (NASDAQ:TPST) stock surged due to a new agreement with Roche Holdings AG to advance a Phase 3 trial for liver cancer treatment. The trial will evaluate the combination of amezalpat with atezolizumab and bevacizumab. Tempest retains all rights to amezalpat, and the stock rose 23% in premarket trading.

Portfolio Pulse from Vandana Singh

October 10, 2024 | 1:06 pm

FRGT

Freight Technologies has regained compliance with Nasdaq's minimum bid price requirement, resolving its previous listing issue.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 1:05 pm

AMZN

Amazon's Prime Big Deal Days 2024 was the company's largest October shopping event ever, with more Prime members participating and over $1 billion saved globally. This marks a strong start to the holiday shopping season.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 1:03 pm

KNDI

Kandi Technologies announced that Chairman Xiaoming Hu is stepping down after decades of service. He will remain on the board as a director to support the company's strategic transition aimed at long-term growth and enhancing shareholder value.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 1:01 pm